AMRX NASDAQ
Amneal Pharmaceuticals, Inc.
1W: +8.6%
1M: +6.3%
3M: +12.1%
YTD: +66.0%
1Y: +101.7%
3Y: +495.5%
5Y: +276.7%
$21.44
+0.42 (+2.00%)
After Hours: $21.23 (-0.21, -0.96%)
Weekly Expected Move ±4.0%
$19
$20
$20
$21
$22
Credit Risk of going bust: lower than 58% of companies Debt: 29.4% of company value Bonds: $58.6M held by 128 funds, 178 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.71B.
Distance to default 5.91 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.51. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.71B.
Distance to default 5.91 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.51. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$3B
Revenue
+9.3% YoY
$157M
Net Income
+4562.6% YoY
$83M
Free Cash Flow
-68.3% YoY
42.0%
Gross Margin
18.3%
Op. Margin
7.2%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-395.8%
ROA4.4%
ROIC16.0%
Valuation
P/E43.0
P/B206.6
EV/EBITDA12.8
Leverage
Debt/Equity84.54
Current Ratio2.20
Interest Cov.2.0x
Quality Scores
Piotroski F8/9
Altman Z2.34
Beneish M-2.42